At the news
? NEUTRALIMPACT 3/10 SC 13G/A filed Nov 5, 2026 at 13:24 ET
FMR LLC (Fidelity) filed an amended Schedule 13G disclosing a 7.2% passive stake in Revolution Medicines as of September 30, 2026, up from a prior filing. The increase reflects Fidelity's continued accumulation following the company's strong Q3 earnings beat from its newly approved drug RASONQUE.
- FMR LLC (Fidelity) reported beneficial ownership of 15,402,102.97 shares of Revolution Medicines common stock as of September 30, 2026.
- The stake represents 7.2% of shares outstanding.
- This is an amendment to a prior Schedule 13G filing, indicating an increase from the previously reported position.
- The filing is passive (Rule 13d-1(b)), with no intent to influence control.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access